All analyses
5 min read

Last updated:

Thyroid and fatigue: what a slightly high TSH really means

TSH is the most frequently ordered test when fatigue persists, and the box most often ticked to explain what is wrong. Yet two large trials tested the idea directly: correcting a slightly elevated TSH improves neither fatigue nor symptoms. And in a third of cases, the number comes back down on its own.

10 studies citedsee the sources

Benjamin Sant

Co-founder of the School of Longevity

Prevention consultation, discussion of laboratory results
Prevention consultation, discussion of laboratory results

Behind a TSH slightly above the reference range

Subclinical hypothyroidism is diagnosed when TSH exceeds the laboratory's upper limit while free thyroxine remains normal. It is a purely biological definition: it says nothing about the person's symptoms, and it does not describe a disease in the usual sense.

The limit itself is not a constant of nature. A German study showed that the TSH reference interval shifted in the same population after iodine supply improved. A person classified outside the range in one laboratory may be within the range of another.

For a practitioner, the first consequence is not to treat the excess as an established fact. An isolated TSH, sampled once, in a context of fatigue, does not constitute a diagnosis. It constitutes a question put to the physician.

A third of cases normalize without doing anything

The natural history of this situation is well documented and it surprises. A prospective cohort of 107 patients over 55, followed for a mean of 31.7 months, found that 26.8 percent progressed to overt hypothyroidism, but that 37.4 percent saw their TSH normalize spontaneously.

The starting level decides almost everything. In this same cohort, the incidence of overt hypothyroidism was 1.76 cases per 100 patient-years when initial TSH was between 5.0 and 9.9 mU/L, 19.67 between 10.0 and 14.9, and 73.47 between 15.0 and 19.9.

A more recent series of 241 patients with a TSH of 10 or less confirms the picture: 19 percent eventually required treatment, 22.8 percent normalized spontaneously, and 58.1 percent stayed exactly where they were. Only an initial TSH above 8 predicted the need for treatment.

The trial that tested the question directly

The TRUST trial randomized older adults with subclinical hypothyroidism between levothyroxine and placebo. Mean age 74.4, 53.7 percent women, mean baseline TSH 6.40 mIU/L.

Treatment did what was expected of it biologically: at one year, TSH had fallen to 3.63 in the treated group against 5.48 on placebo, for a median dose of 50 µg. On symptoms, nothing. The between-group difference on the hypothyroidism symptom score was 0.0, confidence interval -2.0 to 2.1.

On fatigue, measured separately, the difference was 0.4, interval -2.1 to 2.9. No benefit appeared on secondary outcomes either. The number was corrected, the person did not feel better.

Twenty-one trials reach the same result

TRUST is not an isolated accident. A meta-analysis published in JAMA pooled 21 randomized trials and 2,192 adults, with treatment durations of 3 to 18 months.

Treatment brought TSH back into the normal range, 0.5 to 3.7 mIU/L against 4.6 to 14.7 on placebo. It was associated with no benefit on general quality of life, standardized difference -0.11 with an interval of -0.25 to 0.03, nor on thyroid symptoms, difference 0.01 with an interval of -0.12 to 0.14.

Risk of bias was judged low and the quality of evidence, assessed with the GRADE tool, moderate to high. It is on this basis that a clinical practice guideline published in the BMJ concluded against treating most adults with subclinical hypothyroidism.

Why fatigue remains a poor entry point

Fatigue is the least specific symptom in medicine. It accompanies insufficient sleep, anemia, depression, a sleep breathing disorder, deconditioning, work overload, and many other things. It also accompanies overt hypothyroidism, which explains the reflex to order TSH.

But a screening reflex is not an explanation. When the test comes back slightly high in a tired person, two readings are possible: the thyroid explains the fatigue, or the two coexist without a link. Trials settle in favor of the second, since correcting the number does not correct the symptom.

That does not mean the test is useless. It rules out overt hypothyroidism, which exists and is treated. It means that a TSH at 6 does not close the investigation, it leaves it open.

The role of a non-physician practitioner facing this result

The decision to treat or not belongs to the physician, and the nuance is real: the 10 mIU/L threshold, thyroid peroxidase antibodies, age, a pregnancy plan and overt symptoms all enter the arbitration. None of the above replaces it.

What a practitioner can do is avoid two opposite errors. The first is to validate the thyroid explanation and stop looking, whereas trials show that correcting the number does not relieve. The second is to dismiss it out of hand, whereas a quarter of cases progress and follow-up has value.

What remains is the background work, which is within their scope. A well-conducted first consultation questionnaire spots in a few minutes shortened sleep, regular alcohol consumption, low mood or collapsed physical activity, that is, causes of fatigue that are more frequent and more accessible. And in the face of fatigue that worsens, comes with weight loss or resists everything, medical referral comes before any hypothesis.

Sources

  1. 1.Stott DJ, et al. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. N Engl J Med. 2017.
  2. 2.Feller M, et al. Association of Thyroid Hormone Therapy With Quality of Life and Thyroid-Related Symptoms in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis. JAMA. 2018.
  3. 3.Bekkering GE, et al. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ. 2019.
  4. 4.Biondi B, et al. Subclinical Hypothyroidism: A Review. JAMA. 2019.
  5. 5.Biondi B, et al. Subclinical hypothyroidism in older individuals. Lancet Diabetes Endocrinol. 2022.
  6. 6.Zijlstra LE, et al. Levothyroxine Treatment and Cardiovascular Outcomes in Older People With Subclinical Hypothyroidism: Pooled Individual Results of Two Randomised Controlled Trials. Front Endocrinol (Lausanne). 2021.
  7. 7.Chen Y, et al. Levothyroxine in the treatment of overt or subclinical hypothyroidism: a systematic review and meta-analysis. Endocr J. 2020.
  8. 8.Díez JJ, et al. Spontaneous subclinical hypothyroidism in patients older than 55 years: an analysis of natural course and risk factors for the development of overt thyroid failure. J Clin Endocrinol Metab. 2004.
  9. 9.Rosário PW, et al. Natural history of subclinical hypothyroidism with TSH ≤10 mIU/l: a prospective study. Clin Endocrinol (Oxf). 2016.
  10. 10.Ittermann T, et al. Shift of the TSH reference range with improved iodine supply in Northeast Germany. Eur J Endocrinol. 2015.

Reading studies is one thing, turning them into a plan is another

The Longevity Practitioner certification teaches the method that turns this kind of data into an accompaniment decision: assess, prioritise, plan over 90 days, re-measure, and know when to hand over.

See the certification

11 modules, €2,200. Enrol

Benjamin Sant

Co-founder of the School of Longevity

Cofounder of the School of Longevity with Tristan Maruyama. A former officer trained at Saint-Cyr from 2019 to 2022 and a coach since 2018, he has supported more than 4,000 people. He leads the School's editorial content with one constant principle: pass on only what can be situated, verified and applied seriously.

This article is published for information and education. It does not replace medical advice. For any personal health question, consult a healthcare professional.